Business Context and Reporting Period
This Form 8-K Current Report was filed by Ultragenyx Pharmaceutical Inc. on March 17, 2016, regarding events occurring on that date. The filing focuses on corporate governance changes rather than financial performance.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to the appointment of a new director and associated compensation.
Material Changes
The primary material change reported is the appointment of Lars Ekman, M.D., Ph.D., as a Class III director effective March 17, 2016. Concurrent with this appointment, the Board of Directors size was fixed at seven members, comprising two Class I, two Class II, and three Class III directors.
Management Commentary and Compensation
Dr. Ekman brings over 30 years of pharmaceutical industry experience, including roles as executive partner at Sofinnova Ventures and former president of R&D at Elan. In connection with his appointment, he will receive compensation consistent with the Company's Non-Employee Director Compensation Policy. Specifically, on March 17, 2016, the Company granted Dr. Ekman a stock option to purchase up to 15,000 shares of common stock with an exercise price of $54.28, based on the closing price on The Nasdaq Global Select Market on that date.
Investor Verification Checklist
- Verify the effective date of Dr. Ekman's directorship (March 17, 2016) and his term expiration at the 2016 annual meeting.
- Confirm the total Board size is now seven directors with the specified class distribution.
- Review the specific terms of the 15,000-share stock option grant, including the $54.28 exercise price.
- Check for any subsequent filings regarding Dr. Ekman's voting record or committee assignments.